Tempest Therapeutics Inc (TPST NASDAQ) stock market data APIs
$6.753
0.24(3.6%)
as of June 30, 2025
Try our APIs with
free plan!
Tempest Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Prev. Close
6.753
Open
6.9976
High
7.0147
Low
6.699
52 wk Range
5.3495-30.03
Market Cap
25 409 K
Shares Outstanding
3 682 K
EPS
-3.16
Beta
-2.328
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tempest Therapeutics Inc data using free add-ons & libraries
Get Tempest Therapeutics Inc Fundamental Data
Tempest Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -44 619 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -3.2933
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tempest Therapeutics Inc News
New
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempe...
Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor
(RTTNews) - Tempest Therapeutics, Inc. (TPST), a clinical-stage biotech firm developing first-in-class targeted and immune-mediated cancer therapies, has entered into a definitive agreement with a sin...
Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%
* Tempest Therapeutics (NASDAQ:TPST [https://seekingalpha.com/symbol/TPST]) announced on Wednesday that it has entered into a definitive agreement with a single institutional investor for the purcha...
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
